Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Sleat
Rbhs Robert Wood Johnson Medical School, Department: Biochemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
BioMarin Pharmaceutical Inc.
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution
Dr. Sleat receives a portion of license revenues and fees from BioMarin Pharmaceutical Inc. The sponsor of the current study is NIH. This study is closely linked with, and overlaps with the focus of the company which is to develop drugs for the treatment of rare diseases. BioMarin has licensed several of the patents held by Drs. Sleat and Lobel. The COIC has reviewed this study in the past and since no financial reward was indicated no COI was assigned. However, now a considerable amount of money has been given to Dr. Sleat and to Dr. Lobel’s laboratory, the University and to CABM. Although Dr. Sleat states that there is no direct connection between the current study and the earnings disclosed, the relatedness between them is apparent. However since the patents no longer belong to Rutgers and have been sold, royalties from them will also cease to accrue to Dr. Sleat. The Committee, by Rutgers Policy, is concerned only with royalties received during the past 12 months.
Biomarker discovery for juvenile neuronal ceroid lipofuscinosis
Juvenile neuronal ceroid lipofuscinosis is a fatal neurodegenerative disease that mostly affects children and which represent a significant medical burden. There is no cure for this disease and identifying potential therapies is hampered by a lack of understanding of the function of the protein (CLN3) that is defective as well as a lack of methods for effective drug screening. This project is focused on the discovery of biochemical tests that can reveal the status of CLN3 function, providing insights into the function of CLN3, establishing valuable tools for discovering new treatments, and greatly facilitating clinical trials in the future.
Filed on November 14, 2016.
Tell us what you know about David Sleat's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Sleat”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Sleat | Rbhs Robert Wood Johnson Medical School | Conflict of Interest | BioMarin Pharmaceutical Inc. | >$600,000 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.